Skip to content
Taurursodiol
Relyvrio (taurursodiol) is a small molecule pharmaceutical. Taurursodiol was first approved as Relyvrio on 2022-09-29. It is used to treat amyotrophic lateral sclerosis in the USA.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
nervous system diseasesD009422
nutritional and metabolic diseasesD009750
Trade Name
FDA
EMA
Combinations
Relyvrio
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Sodium phenylbutyrate
+
Taurursodiol
Tradename
Company
Number
Date
Products
RELYVRIOAmylyx PharmaceuticalsN-216660 RX2022-09-29
1 products, RLD, RS
Labels
FDA
EMA
Brand Name
Status
Last Update
relyvrioNew Drug Application2022-09-30
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
amyotrophic lateral sclerosisEFO_0000253D000690G12.21
Agency Specific
FDA
EMA
Expiration
Code
SODIUM PHENYLBUTYRATE / TAURURSODIOL, RELYVRIO, AMYLYX
2029-09-29ODE-411
2027-09-29NCE
Patent Expiration
Patent
Expires
Flag
FDA Information
Sodium Phenylbutyrate / Taurursodiol, Relyvrio, Amylyx
115835422040-07-27DP
98728652033-12-24U-3460
102518962033-12-24U-3460
108571622033-12-24U-3460
110717422033-12-24DP
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
19 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
GallstonesD042882EFO_0004210———1—1
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Amyotrophic lateral sclerosisD000690EFO_0000253G12.21—11——2
Biliary liver cirrhosisD008105K74.3——1——1
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
AmyloidosisD000686EFO_1001875E8511———1
Type 1 diabetes mellitusD003922EFO_0001359E10—1———1
Multiple sclerosisD009103EFO_0003885G3511———1
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Liver cirrhosisD008103EFO_0001422K74.01————1
AsthmaD001249EFO_0000270J451————1
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Type 2 diabetes mellitusD003924EFO_0001360E11————22
Insulin resistanceD007333EFO_0002614————22
Endoplasmic reticulum stressD059865EFO_1001886————11
ObesityD009765EFO_0001073E66.9————11
Cystic fibrosisD003550EFO_0000390E84————11
CholestasisD002779K83.1————11
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameTAURURSODIOL
INNursodoxicoltaurine
Description
Tauroursodeoxycholic acid is a bile acid taurine conjugate derived from ursoodeoxycholic acid. It has a role as a human metabolite, an anti-inflammatory agent, a neuroprotective agent, an apoptosis inhibitor, a cardioprotective agent and a bone density conservation agent. It is functionally related to an ursodeoxycholic acid. It is a conjugate acid of a tauroursodeoxycholate.
Classification
Small molecule
Drug class—
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C[C@H](CCC(=O)NCCS(=O)(=O)O)[C@H]1CC[C@H]2[C@@H]3[C@@H](O)C[C@@H]4C[C@H](O)CC[C@]4(C)[C@H]3CC[C@@]21C
Identifiers
PDB—
CAS-ID14605-22-2
RxCUI—
ChEMBL IDCHEMBL272427
ChEBI ID80774
PubChem CID9848818
DrugBankDB08834
UNII ID60EUX8MN5X (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 317 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
0 adverse events reported
View more details